Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients

Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients

IntroductionTriple negative breast cancer (TNBC) shows an aggressive growing and spreading behavior and has limited treatment options, often leading to inferior disease outcome. Therefore, surrogate markers are urgently needed to identify patients at high risk of recurrence and more importantly, to...

Full description

Bibliographic Details
Main Authors: Oliver Hoffmann, Sebastian Wormland, Ann-Kathrin Bittner, Julian Hölzenbein, Esther Schwich, Sabine Schramm, Hana Rohn, Peter A. Horn, Rainer Kimmig, Sabine Kasimir-Bauer, Vera Rebmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
triple-negative breast cancer
early breast cancer (EBC)
biomarker
ILT-2 rs10416697C allele
sHLA-G
CTC (circulation tumor cells)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188030/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188030/full

Similar Items